Thrombotic Microangiopathies (TMA): First Report of 250 Cases from a Single Institution Experience in Latin America

CÉLIA DOS SANTOS; MARA AGAZZONI; MAGALI BARRENECHEA; JUVENAL PAIVA; MARÍA M CASINELLI; ANA C KEMPFER; MARÍA L ROMERO; MARÍA A LAZZARI; ANALÍA SÁNCHEZ-LUCEROS

Berlin

Congreso; XXVIth Congress of the ISTH; 2017

ISTH

BACKGROUND: TMA are characterized by microangiopathic hemolytic anemia (MAHA), thrombocytopenia and organ failure. Worldwide, patients? cohort studies have been of great interest to understand pathological mechanisms and develop methods to differentiate entities, specifically between atypical Hemolytic Uremic Syndrome (aHUS) and adquired or congenital Thrombotic Thrombocytopenic Purpura (aTTP/cTTP).AIMS: For the first time, we described laboratory and clinical features of consecutive TMA patients studied in our department.METHODS: A prospective study (n=250) from Jan-2013 until Jun-2016, requiring patients? informed consent, was approved by the institutional Ethical Committee. Laboratory (Technozyme® ADAMTS13 (AD13) activity and IgG anti-AD13, platelets, creatinine, LDH) and clinical parameters were recorded. Mann?Whitney U-test was used to compare parameters across groups (p